Amniotics Phase I/II Study of PulmoStem™ in Hospitalized COVID-19 Patients Ready to Start

Amniotics AB announced that several batches of PulmoStem™ have been certified by the company’s Qualified Person and that clinical sites in the UK and Sweden are set to start the enrollment of subjects in the first-in-human Phase I/II study of hospitalized COVID-19 patients.